Last reviewed · How we verify
Autologous Bone Marrow-Derived Mononuclear Stem Cells
At a glance
| Generic name | Autologous Bone Marrow-Derived Mononuclear Stem Cells |
|---|---|
| Sponsor | Novo Cellular Medicine Institute LLP |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina (PHASE2)
- Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM (PHASE2)
- Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis (PHASE1, PHASE2)
- Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia (PHASE1, PHASE2)
- Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP). (PHASE2)
- IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients (PHASE1, PHASE2)
- BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients (PHASE1, PHASE2)
- Human Umbilical Cord Stroma MSC in Myocardial Infarction (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: